In type 2 diabetes patients and rodent models, SGLT2 inhibitors exhibit neuroprotective properties through reduction of oxidative stress, alleviation of cerebral atherosclerosis and suppression of microglia‐induced neuroinflammation. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.